+Compare
ACAD
Stock ticker:
NASDAQ
AS OF
Jul 1 closing price
Price
$14.37
Change
+$0.28 (+1.99%)
Capitalization
2.32B

ACAD Price Prediction, ACADIA Pharmaceuticals AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Jun 16, 2022

Aroon Indicator for ACAD shows an upward move is likely

ACAD's Aroon Indicator triggered a bullish signal on June 16, 2022. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 218 similar instances where the Aroon Indicator showed a similar pattern. In 186 of the 218 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 14, 2022. You may want to consider a long position or call options on ACAD as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ACAD moved above its 50-day moving average on June 16, 2022 date and that indicates a change from a downward trend to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ACAD advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where ACAD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ACAD broke above its upper Bollinger Band on June 16, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.216) is normal, around the industry mean (24.469). P/E Ratio (0.000) is within average values for comparable stocks, (93.841). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.919). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (4.686) is also within normal values, averaging (306.529).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ACAD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

ACAD is expected to report earnings to fall 64.73% to -24 cents per share on August 03

ACADIA Pharmaceuticals ACAD Stock Earnings Reports
Q2'22
Est.
$-0.25
Q1'22
Missed
by $0.08
Q4'21
Missed
by $0.03
Q3'21
Beat
by $0.17
Q2'21
Beat
by $0.03
The last earnings report on May 04 showed earnings per share of -69 cents, missing the estimate of -61 cents. With 1.58M shares outstanding, the current market capitalization sits at 2.32B.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Global Blood Therapeutics (NASDAQ:GBT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.73B. The market cap for tickers in the group ranges from 2.5K to 250.34B. NONOF holds the highest valuation in this group at 250.34B. The lowest valued company is IMUND at 2.5K.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was -36%. EVFM experienced the highest price growth at 145%, while PCNTD experienced the biggest fall at -81%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -54%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -18 (-100 ... +100)
AI

View a ticker or compare two or three

AI
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals drugs for treatment of central nervous system disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12830 El Camino Real
Phone
+1 858 558-2871
Employees
514
Web
https://www.acadia-pharm.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSUAX22.630.29
+1.30%
Cohen & Steers Global Infrastructure A
EQNSX17.600.16
+0.92%
MFS Equity Income R2
RKCIX7.790.07
+0.88%
Rockefeller Climate Solutions Instl
FMQSX12.940.10
+0.78%
Franklin Mutual Quest R
FUEPX48.11-0.06
-0.12%
American Funds Europacific Growth 529F2

ACAD and

Correlation & Price change

A.I.dvisor tells us that ACAD and NMTR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACAD and NMTR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+1.99%
NMTR - ACAD
32%
Poorly correlated
-13.77%
ROIV - ACAD
29%
Poorly correlated
+8.60%
ALLK - ACAD
29%
Poorly correlated
-3.51%
EQRX - ACAD
28%
Poorly correlated
-2.99%
GTBP - ACAD
27%
Poorly correlated
-3.68%
More